Arvinas Announces Changes to its Board of Directors

Posted: December 18, 2022 at 12:22 am

NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has been appointed to join.

See the original post:
Arvinas Announces Changes to its Board of Directors

Related Posts